Key result
Oral cilazapril did not reduce intimal thickening over 3 months in baboon arterial injury models compared to untreated controls.
Why the study?
Does oral cilazapril reduce intimal hyperplasia in injured arteries and vascular grafts in a baboon model?
Does oral cilazapril reduce intimal hyperplasia in injured arteries and vascular grafts in a baboon model?
In a baboon model of arterial injury, ACE inhibition with cilazapril did not significantly reduce intimal thickening over 3 months.
Answers are grounded in this paper and cite their sources.
Negative baboon result tempers expectations for ACE inhibition in vascular injury; leaves open human translation.
To determine the importance of angiotensin converting enzyme (ACE) activity in the development of arterial proliferative lesions in a primate model, the response to vascular injury was studied in five baboons treated with oral cilazapril (20 mg/kg/day) and in five untreated control animals. Each animal underwent three procedures: 1) carotid artery endarterectomy, 2) balloon catheter deendothelialization of the superficial femoral artery, and 3) surgical placement of bilateral aorto-iliac expanded polytetrafluoroethylene (Gore-Tex) vascular grafts. Cilazapril therapy was initiated 1 week preoperatively and continued throughout the study interval. At 1 and 3 weeks postoperatively, plasma ACE activity was inhibited by more than 96% versus control values. After animals were killed at 3 months, injured vessel and graft segments were evaluated morphometrically. Although the response between animals was variable, average cross-sectional areas of neointima did not differ between the cilazapril-treated and control groups at sites of carotid endarterectomy (0.26 +/- 0.12 versus 0.34 +/- 0.17 mm2, respectively; p greater than 0.5), femoral artery ballooning (0.15 +/- 0.08 versus 0.11 +/- 0.01 mm2; p greater than 0.5), or at graft anastomoses (1.86 +/- 0.50 versus 1.72 +/- 0.50 mm2; p greater than 0.5). Thus, cilazapril did not reduce intimal thickening over 3 months in these primate arterial injury models. However, a possible beneficial effect of cilazapril, which might be apparent at earlier time points or with larger animal groups, cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Hanson et al. (1991) studied Arterial proliferative lesions / intimal hyperplasia (n=10). Cilazapril vs. Untreated control was evaluated on Cross-sectional area of neointima at sites of carotid endarterectomy, femoral artery ballooning, or graft anastomoses (p=>0.5). Oral cilazapril did not reduce intimal thickening over 3 months in baboon arterial injury models compared to untreated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: